If you're reading this, you're probably trying to figure out whether to ask your doctor about Ozempic or Mounjaro. It's the single most common question in GLP-1 forums, support groups, and doctor's offices — and the answer isn't as simple as "this one is better."
They work differently. They produce different results. They cost different amounts. And depending on your specific situation, either one could be the right choice.
Let's get into it.
The fundamental difference
This matters more than most comparison articles will tell you.
Ozempic (semaglutide) is a GLP-1 receptor agonist. It mimics one gut hormone — GLP-1 — which reduces appetite, slows gastric emptying, and improves blood sugar regulation.
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist. It mimics two gut hormones simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism appears to produce greater metabolic effects than targeting GLP-1 alone, including more weight loss, greater insulin sensitivity improvements, and potentially different side effect patterns.
This isn't a marketing distinction. The dual-agonist approach is a genuinely different pharmacological strategy, and the clinical data reflects it.
Weight loss: the numbers
This is what most people want to know, so let's be direct.
The SURMOUNT-5 trial was the first head-to-head comparison of tirzepatide versus semaglutide at their maximum approved doses for weight management. The results were clear: tirzepatide (Zepbound 15mg) produced 20.2% mean weight loss versus 13.7% for semaglutide (Wegovy 2.4mg) over 72 weeks (Aronne et al., 2025). That's roughly 47% more weight loss with tirzepatide.
Now, Ozempic specifically maxes out at 2.0mg — lower than the 2.4mg Wegovy dose used in that trial. So Ozempic's expected weight loss is somewhat less than 13.7%.
It's worth noting that Wegovy HD (semaglutide 7.2mg) was approved in March 2026 and showed 20.7% mean weight loss in the STEP UP trial (Wharton et al., 2025). At the highest available semaglutide dose, the weight loss gap with tirzepatide narrows considerably — but Ozempic doesn't go that high. Ozempic tops out at 2.0mg.
For diabetes-specific outcomes: both medications dramatically improve blood sugar control. In the SURPASS trials, tirzepatide at 15mg reduced HbA1c by up to 2.4 percentage points, while semaglutide at comparable doses typically achieves 1.5-1.8 percentage point reductions. The ACHIEVE-3 trial also showed Eli Lilly's oral orforglipron outperforming oral semaglutide on HbA1c — signalling that Lilly's GLP-1 platform may have a consistent efficacy edge.
Side effects: broadly similar, with nuances
Both medications share the GLP-1 side effect profile: nausea, vomiting, diarrhoea, constipation, and abdominal pain. These are most common during dose escalation and typically improve over time.
A comprehensive analysis of gastrointestinal tolerability across the SURMOUNT clinical trials found that nausea was the most frequently reported side effect, peaking during dose escalation and generally resolving at stable doses (Rubino et al., 2025). The pattern is similar for semaglutide.
Some practical differences users report:
Mounjaro may cause slightly less nausea but more diarrhoea than Ozempic, though this varies enormously between individuals. Some people who couldn't tolerate semaglutide do fine on tirzepatide, and vice versa. If one doesn't work for you, it's absolutely worth trying the other.
Hair thinning (telogen effluvium) is reported with both medications and is associated with the rate of weight loss rather than the specific drug (Daneshgaran et al., 2025). Because tirzepatide tends to produce faster weight loss, this may be slightly more common — though no head-to-head hair-specific studies exist.
Cost and access in 2026
Ozempic runs approximately $900-$1,000/month at list price. Insurance coverage through the diabetes pathway is generally well-established. Crucially, semaglutide's core US patent expired March 20, 2026, meaning generic alternatives are on the horizon and could dramatically reduce costs.
Mounjaro runs approximately $1,000-$1,100/month at list price. Insurance coverage for diabetes is comparable to Ozempic. Tirzepatide's patents extend well into the 2030s — there will be no generic tirzepatide for years.
This patent situation creates an interesting dynamic. As generic semaglutide enters the market, the cost advantage will shift significantly toward semaglutide products. Whether tirzepatide's superior weight loss justifies a persistent price premium is a calculation each patient and insurer will need to make.
Both Novo Nordisk and Eli Lilly have introduced direct-to-consumer discount programmes. The Trump administration's 2025 agreements brought some GLP-1 prices down to $245/month for eligible patients.
Approved uses
Ozempic: Type 2 diabetes (2017). Cardiovascular risk reduction in adults with type 2 diabetes (2020).
Mounjaro: Type 2 diabetes (2022). Its weight-loss cousin, Zepbound, is approved for weight management. Mounjaro itself is frequently prescribed off-label for weight loss, though Zepbound is the official weight-loss product.
Both are once-weekly subcutaneous injections. Neither currently has an oral formulation — though Wegovy (semaglutide's weight-loss brand) now does, and Eli Lilly's oral orforglipron is expected to gain FDA approval in 2026.
What about cardiovascular protection?
Semaglutide has the strongest cardiovascular evidence in the GLP-1 space. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (Lincoff et al., 2023). Wegovy has a specific FDA indication for cardiovascular risk reduction. Ozempic has cardiovascular outcome data in people with type 2 diabetes (the SUSTAIN-6 trial showed a 26% reduction in MACE).
Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is still ongoing. Early signals are promising — the cardiometabolic improvements are at least as good as semaglutide — but the definitive data isn't published yet. If cardiovascular protection is a primary treatment goal, semaglutide currently has the stronger evidence base.
So which one should you ask about?
Lean toward Ozempic if: You have type 2 diabetes as your primary condition. You value the extensive long-term safety data (semaglutide has been studied since 2012). Cost matters and you want access to upcoming generic options. You have established cardiovascular disease and want the most evidence-backed cardiac protection.
Lean toward Mounjaro if: Maximum weight loss is your primary goal. You haven't responded adequately to semaglutide. You can tolerate semaglutide's side effects — tirzepatide's GI profile may differ enough to work better for you. Your insurance covers it comparably to Ozempic.
The honest answer: Both are remarkable medications. Tirzepatide produces more weight loss on average. Semaglutide has more long-term data, a cardiovascular indication, more formulation options, and will soon be dramatically cheaper. Your doctor, your insurance, and your body's response will ultimately determine which is better for you specifically.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from.
-
Aronne et al. (2025) — The SURMOUNT-5 trial, the first direct head-to-head comparison of tirzepatide versus semaglutide at maximum approved weight-loss doses, showing 20.2% vs 13.7% weight loss favouring tirzepatide over 72 weeks. Read the full study
-
Wharton et al. (2025) — The STEP UP trial demonstrating semaglutide 7.2mg achieved 20.7% mean weight loss, narrowing the gap with tirzepatide at the highest available semaglutide dose. Read the full study
-
Lincoff et al. (2023) — The SELECT trial showing semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease — the strongest cardiac outcome data for any GLP-1. Read the full study
-
Rubino et al. (2025) — Comprehensive gastrointestinal tolerability analysis across the SURMOUNT trial programme, confirming that nausea peaks during dose escalation and generally resolves at stable doses. Read the full study
-
Daneshgaran et al. (2025) — Systematic review showing hair thinning with GLP-1 medications is primarily telogen effluvium driven by rapid weight loss, not the medication itself. Read the full study